These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 22537261)

  • 21. Considerations in sirolimus use in the early and late post-transplant periods.
    Patel SJ; Elliott EN; Knight RJ; Gaber LW; Gaber AO
    Expert Opin Drug Saf; 2009 Jul; 8(4):421-34. PubMed ID: 19522662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Dialysis and renal transplantation. Update 2012].
    Riegel W; Krüger B; Schnülle P
    Dtsch Med Wochenschr; 2012 Dec; 137(49):2567-70. PubMed ID: 23188637
    [No Abstract]   [Full Text] [Related]  

  • 23. Dramatic regression of recalcitrant human papillomavirus type 1-related palmar verrucae and squamous cell carcinoma in situ following R-CHOP chemotherapy and transition to sirolimus in a renal transplant patient with diffuse large B cell lymphoma.
    Vance KK; Krunic AL; Fishman PM; Kadkol SS; Nuovo GJ
    Int J Dermatol; 2015; 54(5):e119-21. PubMed ID: 25039383
    [No Abstract]   [Full Text] [Related]  

  • 24. The use of everolimus in pediatric kidney transplantation.
    Tönshoff B
    Pediatr Transplant; 2014 Jun; 18(4):323-4. PubMed ID: 24802339
    [No Abstract]   [Full Text] [Related]  

  • 25. mTOR Inhibition and Kidney Diseases.
    Ma MKM; Yung S; Chan TM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus.
    Zaltzman JS; Prasad R; Chun K; Jothy S
    Nephrol Dial Transplant; 2005 Aug; 20(8):1748-51. PubMed ID: 15919698
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.
    Chhabra D; Alvarado A; Dalal P; Leventhal J; Wang C; Sustento-Reodica N; Najafian N; Skaro A; Levitsky J; Mas V; Gallon L
    Am J Transplant; 2013 Nov; 13(11):2902-11. PubMed ID: 24007570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sirolimus for the treatment of Kaposi sarcoma after renal transplantation: a series of 10 cases.
    Yaich S; Charfeddine K; Zaghdane S; El Aoud N; Jarraya F; Kharrat M; Hachicha J
    Transplant Proc; 2012 Nov; 44(9):2824-6. PubMed ID: 23146533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus: an immunosuppressive agent in transplantation.
    Patel JK; Kobashigawa JA
    Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sirolimus and secondary skin-cancer prevention in kidney transplantation.
    Euvrard S; Morelon E; Rostaing L; Goffin E; Brocard A; Tromme I; Broeders N; del Marmol V; Chatelet V; Dompmartin A; Kessler M; Serra AL; Hofbauer GF; Pouteil-Noble C; Campistol JM; Kanitakis J; Roux AS; Decullier E; Dantal J;
    N Engl J Med; 2012 Jul; 367(4):329-39. PubMed ID: 22830463
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion to sirolimus therapy in kidney transplant recipients with new onset diabetes mellitus after transplantation.
    Veroux M; Tallarita T; Corona D; Sinagra N; Giaquinta A; Zerbo D; Guerrieri C; D'Assoro A; Cimino S; Veroux P
    Clin Dev Immunol; 2013; 2013():496974. PubMed ID: 23762090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sirolimus antirejection therapy for renal transplantation with cyclosporine-based immunosuppression: case reports.
    Tsai MK; Hu RH; Lee PH
    Transplant Proc; 2003 Feb; 35(1):219-20. PubMed ID: 12591371
    [No Abstract]   [Full Text] [Related]  

  • 33. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus.
    Hoogendijk-van den Akker JM; Harden PN; Hoitsma AJ; Proby CM; Wolterbeek R; Bouwes Bavinck JN; de Fijter JW
    J Clin Oncol; 2013 Apr; 31(10):1317-23. PubMed ID: 23358973
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Belatacept reduces skin cancer risk in kidney transplant recipients.
    Wang M; Mittal A; Colegio OR
    J Am Acad Dermatol; 2020 Apr; 82(4):996-998. PubMed ID: 31589945
    [No Abstract]   [Full Text] [Related]  

  • 35. Can Rapamune replace cyclosporine? No significant difference in rejection rate after six months; long-term studies needed.
    Nephrol News Issues; 2000 Aug; 14(9):S9-10. PubMed ID: 11933435
    [No Abstract]   [Full Text] [Related]  

  • 36. Measuring adherence to medications: are complex methods superior to simple ones?
    Shemesh E
    Pediatr Transplant; 2012 Jun; 16(4):315-7. PubMed ID: 22452614
    [No Abstract]   [Full Text] [Related]  

  • 37. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience.
    Kahan BD; Knight R; Schoenberg L; Pobielski J; Kerman RH; Mahalati K; Yakupoglu Y; Aki FT; Katz S; Van Buren CT
    Transplant Proc; 2003 May; 35(3 Suppl):25S-34S. PubMed ID: 12742465
    [No Abstract]   [Full Text] [Related]  

  • 38. mTOR inhibitor-associated proteinuria in kidney transplant recipients.
    Diekmann F; Andrés A; Oppenheimer F
    Transplant Rev (Orlando); 2012 Jan; 26(1):27-9. PubMed ID: 22137729
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sirolimus. AY 22989, NSC 226080, NSC 606698, rapamycin, Rapamune.
    Drugs R D; 1999 Jan; 1(1):100-7. PubMed ID: 10566001
    [No Abstract]   [Full Text] [Related]  

  • 40. Rapamycin use and rapid withdrawal of calcineurin inhibitors in pediatric renal transplantation.
    Vilalta R; Vila A; Nieto J; Callís L
    Transplant Proc; 2003 Mar; 35(2):703-4. PubMed ID: 12644102
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.